FASN and pancreatic ductal adenocarcinoma: For example, activated epidermal growth factor receptor (EGFR) was shown to upregulate FASN in pancreatic ductal carcinoma and reciprocally, silencing or inhibition with small molecule inhibitor Erlotinib abolished FASN upregulation [78].